TW201613594A - Pharmaceutical composition containing diamino heteroring carboxamide derivatives - Google Patents
Pharmaceutical composition containing diamino heteroring carboxamide derivativesInfo
- Publication number
- TW201613594A TW201613594A TW104103756A TW104103756A TW201613594A TW 201613594 A TW201613594 A TW 201613594A TW 104103756 A TW104103756 A TW 104103756A TW 104103756 A TW104103756 A TW 104103756A TW 201613594 A TW201613594 A TW 201613594A
- Authority
- TW
- Taiwan
- Prior art keywords
- axl
- cancer
- another embodiment
- treating
- heteroring
- Prior art date
Links
- 229940053202 antiepileptics carboxamide derivative Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 6
- 201000011510 cancer Diseases 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 4
- 230000004913 activation Effects 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- -1 heterocyclic carboxamide compounds Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014-019226 | 2014-02-04 | ||
| JP2014019226 | 2014-02-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201613594A true TW201613594A (en) | 2016-04-16 |
| TWI655945B TWI655945B (zh) | 2019-04-11 |
Family
ID=53777926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW104103756A TWI655945B (zh) | 2014-02-04 | 2015-02-04 | 以二胺基雜環羧醯胺化合物作爲有效成分之醫藥組成物 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US11045468B2 (zh) |
| EP (1) | EP3103453B1 (zh) |
| JP (1) | JP6390626B2 (zh) |
| KR (1) | KR102322338B1 (zh) |
| CN (3) | CN116509866A (zh) |
| AU (1) | AU2015215578B2 (zh) |
| BR (1) | BR112016017897A8 (zh) |
| CA (1) | CA2938818C (zh) |
| CY (1) | CY1122968T1 (zh) |
| DK (1) | DK3103453T3 (zh) |
| EA (1) | EA033304B1 (zh) |
| ES (1) | ES2788390T3 (zh) |
| HR (1) | HRP20200662T1 (zh) |
| HU (1) | HUE049437T2 (zh) |
| IL (1) | IL247077B (zh) |
| LT (1) | LT3103453T (zh) |
| ME (1) | ME03775B (zh) |
| MX (1) | MX363543B (zh) |
| MY (1) | MY193536A (zh) |
| PH (1) | PH12016501527A1 (zh) |
| PL (1) | PL3103453T3 (zh) |
| PT (1) | PT3103453T (zh) |
| RS (1) | RS60150B1 (zh) |
| SG (1) | SG11201606413RA (zh) |
| SI (1) | SI3103453T1 (zh) |
| TW (1) | TWI655945B (zh) |
| UA (1) | UA120607C2 (zh) |
| WO (1) | WO2015119122A1 (zh) |
| ZA (1) | ZA201605379B (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2788390T3 (es) * | 2014-02-04 | 2020-10-21 | Astellas Pharma Inc | Composición médica que comprende un compuesto heterocíclico de diamino-carboxamida como principio activo |
| FI3318259T3 (fi) | 2015-07-03 | 2023-03-20 | Astellas Pharma Inc | Stabiili farmaseuttinen koostumus annettavaksi suun kautta |
| US10744134B2 (en) | 2015-11-04 | 2020-08-18 | Astellas Pharma Inc. | Pharmaceutical composition for cancer immunotherapy and/or immunological activation containing diamino heterocyclic carboxamide compound as active ingredient |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2022220227A1 (ja) * | 2021-04-14 | 2022-10-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | テトラヒドロピリドピリミジン化合物 |
| US11945785B2 (en) | 2021-12-30 | 2024-04-02 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of FLT3 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110110923A1 (en) * | 2008-02-12 | 2011-05-12 | The Brigham And Women's Hospital, Inc. | Fish assay for eml4 and alk fusion in lung cancer |
| WO2009117097A1 (en) | 2008-03-19 | 2009-09-24 | Chembridge Corporation | Novel tyrosine kinase inhibitors |
| UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| PL2428508T3 (pl) * | 2009-05-08 | 2016-05-31 | Astellas Pharma Inc | Diaminoheterocykliczny związek karboksyamidowy |
| CN102408411B (zh) | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| KR20140105765A (ko) * | 2011-11-21 | 2014-09-02 | 이뮤노젠 아이엔씨 | EGfr 항체 세포독성제 접합체에 의한 EGfr 치료에 내성을 나타내는 종양의 치료 방법 |
| UA113204C2 (xx) * | 2012-04-02 | 2016-12-26 | Селективна екстракція хлориду калію з відхідного шенітового розчину з використанням тартратної кислоти як безпечного м'якого екстрагента, придатного до рециркуляції | |
| KR20240005211A (ko) * | 2012-11-21 | 2024-01-11 | 얀센 바이오테크 인코포레이티드 | 이중특이성 EGFR/c-Met 항체 |
| ES2788390T3 (es) * | 2014-02-04 | 2020-10-21 | Astellas Pharma Inc | Composición médica que comprende un compuesto heterocíclico de diamino-carboxamida como principio activo |
| WO2015127234A1 (en) | 2014-02-20 | 2015-08-27 | Board Of Regents, The University Of Texas System | Use of ibrutinib to treat egfr mutant cancer |
| FI3318259T3 (fi) * | 2015-07-03 | 2023-03-20 | Astellas Pharma Inc | Stabiili farmaseuttinen koostumus annettavaksi suun kautta |
-
2015
- 2015-02-03 ES ES15746276T patent/ES2788390T3/es active Active
- 2015-02-03 BR BR112016017897A patent/BR112016017897A8/pt active IP Right Grant
- 2015-02-03 JP JP2015560991A patent/JP6390626B2/ja active Active
- 2015-02-03 HU HUE15746276A patent/HUE049437T2/hu unknown
- 2015-02-03 UA UAA201609187A patent/UA120607C2/uk unknown
- 2015-02-03 ME MEP-2020-77A patent/ME03775B/me unknown
- 2015-02-03 DK DK15746276.3T patent/DK3103453T3/da active
- 2015-02-03 AU AU2015215578A patent/AU2015215578B2/en active Active
- 2015-02-03 KR KR1020167022660A patent/KR102322338B1/ko active IP Right Grant
- 2015-02-03 WO PCT/JP2015/053018 patent/WO2015119122A1/ja active Application Filing
- 2015-02-03 CA CA2938818A patent/CA2938818C/en active Active
- 2015-02-03 MY MYPI2016702813A patent/MY193536A/en unknown
- 2015-02-03 CN CN202310702543.7A patent/CN116509866A/zh active Pending
- 2015-02-03 LT LTEP15746276.3T patent/LT3103453T/lt unknown
- 2015-02-03 PL PL15746276T patent/PL3103453T3/pl unknown
- 2015-02-03 SG SG11201606413RA patent/SG11201606413RA/en unknown
- 2015-02-03 EA EA201691570A patent/EA033304B1/ru not_active IP Right Cessation
- 2015-02-03 MX MX2016010134A patent/MX363543B/es unknown
- 2015-02-03 EP EP15746276.3A patent/EP3103453B1/en active Active
- 2015-02-03 SI SI201531179T patent/SI3103453T1/sl unknown
- 2015-02-03 US US15/116,736 patent/US11045468B2/en active Active
- 2015-02-03 CN CN202110880188.3A patent/CN113425727A/zh active Pending
- 2015-02-03 RS RS20200432A patent/RS60150B1/sr unknown
- 2015-02-03 PT PT157462763T patent/PT3103453T/pt unknown
- 2015-02-03 CN CN201580006772.9A patent/CN105939714A/zh active Pending
- 2015-02-04 TW TW104103756A patent/TWI655945B/zh active
-
2016
- 2016-08-02 IL IL247077A patent/IL247077B/en active IP Right Grant
- 2016-08-03 PH PH12016501527A patent/PH12016501527A1/en unknown
- 2016-08-04 ZA ZA2016/05379A patent/ZA201605379B/en unknown
-
2020
- 2020-04-24 HR HRP20200662TT patent/HRP20200662T1/hr unknown
- 2020-04-28 CY CY20201100384T patent/CY1122968T1/el unknown
-
2021
- 2021-05-21 US US17/327,337 patent/US11925638B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501527A1 (en) | Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient | |
| TW201613901A (en) | New compounds | |
| WO2015070224A3 (en) | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| MX2018000419A (es) | Derivados de amida sustituida que tienen actividad multimodal contra el dolor. | |
| MX2017002816A (es) | Derivados de pirazolopiridina y su uso en terapia. | |
| MX2016004114A (es) | Derivados de 1,4-dihidrodioxina fusionada como inhibidores del factor de trascripcion de choque termico 1. | |
| PH12016500978A1 (en) | Piperazine derivatives having multimodal activity against pain | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| PT3279210T (pt) | Péptido com atividade anticancerígena, composição farmacêutica e composição de suplementos alimentares para prevenção e tratamento do cancro, ambos os quais contêm o mesmo ingrediente ativo | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| WO2019043176A3 (en) | HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| PH12016502313A1 (en) | Pharmaceutical composition comprising pyrazine carboxamide compound as active ingredient | |
| MY197664A (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
| MX2016004094A (es) | Composicion farmaceutica que comprende capecitabina y ciclofosfamida. | |
| MX2018014136A (es) | Derivados de tetrahidropirano y tiopirano que tienen actividad multimodal contra el dolor. | |
| TN2018000091A1 (en) | Oxa-diazaspiro compounds having activity against pain | |
| MX2017008879A (es) | Composicion farmaceutica para el tratamiento de la micosis. | |
| MX2018015240A (es) | Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica. | |
| MX2018004774A (es) | Derivados de morfolina sustituidos que tienen actividad contra el dolor. | |
| MX2017007648A (es) | Composicion farmaceutica que comprende compuesto biciclico de amida heterociclica aromatica que contiene nitrogeno como ingrediente activo. | |
| MX2018000418A (es) | Derivados de amida que tienen actividad multimodal contra el dolor. | |
| TH169730B (th) | องค์ประกอบทางเภสัชกรรมที่ประกอบรวมด้วยสารประกอบ ไดอะมิโนเฮเทอโรไซคลิกคาร์บอกซาไมด์ดังส่วน ผสมออกฤทธิ์ | |
| MX2015012393A (es) | Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina. |